IL143690D0 - The use of growth hormone secretagogues to treat systemic lupus erythematosus and inflammatory bowel disease - Google Patents

The use of growth hormone secretagogues to treat systemic lupus erythematosus and inflammatory bowel disease

Info

Publication number
IL143690D0
IL143690D0 IL14369001A IL14369001A IL143690D0 IL 143690 D0 IL143690 D0 IL 143690D0 IL 14369001 A IL14369001 A IL 14369001A IL 14369001 A IL14369001 A IL 14369001A IL 143690 D0 IL143690 D0 IL 143690D0
Authority
IL
Israel
Prior art keywords
use
growth hormone
inflammatory bowel
bowel disease
lupus erythematosus
Prior art date
Application number
IL14369001A
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US21252100P priority Critical
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of IL143690D0 publication Critical patent/IL143690D0/en

Links

IL14369001A 2000-06-19 2001-06-11 The use of growth hormone secretagogues to treat systemic lupus erythematosus and inflammatory bowel disease IL143690D0 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US21252100P true 2000-06-19 2000-06-19

Publications (1)

Publication Number Publication Date
IL143690D0 true IL143690D0 (en) 2002-04-21

Family

ID=22791370

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14369001A IL143690D0 (en) 2000-06-19 2001-06-11 The use of growth hormone secretagogues to treat systemic lupus erythematosus and inflammatory bowel disease

Country Status (8)

Country Link
US (1) US20020013320A1 (en)
EP (1) EP1166778A3 (en)
JP (1) JP2002053493A (en)
AU (1) AU5198301A (en)
CA (1) CA2350857A1 (en)
HU (1) HU0102500A3 (en)
IL (1) IL143690D0 (en)
ZA (1) ZA200104923B (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1735055A1 (en) * 2004-03-30 2006-12-27 Sapphire Therapeutics, Inc. Method of reducing c-reactive protein using growth hormone secretagogues
JP2008505978A (en) * 2004-07-12 2008-02-28 アラーガン、インコーポレイテッドAllergan,Incorporated Ophthalmic composition and eye disease treatment method
EP1757290A1 (en) * 2005-08-16 2007-02-28 Zentaris GmbH Novel triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors
PE20080145A1 (en) 2006-03-21 2008-02-11 Janssen Pharmaceutica Nv Tetrahydro-pirimidoazepinas as TRPV1 modulators
ES2558928T3 (en) 2007-01-31 2016-02-09 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
JP5631201B2 (en) 2007-03-28 2014-11-26 プレジデント アンド フェローズ オブ ハーバード カレッジ Stitched polypeptide
CL2008003749A1 (en) 2007-12-17 2010-01-15 Janssen Pharmaceutica Nv Compounds derived from imidazole, oxazole, and thiazole pyrimidine, modulators of TRPV1, process preparation, pharmaceutical composition and use in treating diseases, disorders or condition of pain, itching, arthritis, cough, asthma, disorder the inner ear and disease inflammatory bowel, among others.
CA2755779C (en) * 2009-03-20 2015-11-10 Antares Pharma, Inc. Hazardous agent injection system
RU2582678C2 (en) 2010-08-13 2016-04-27 Эйлерон Терапьютикс, Инк. Peptidomimetic macrocycles
EP2431035A1 (en) 2010-09-16 2012-03-21 Æterna Zentaris GmbH Novel Triazole Derivatives with Improved Receptor Activity and Bioavailability Properties as Ghrelin Antagonists of Growth Hormone Secretagogue Receptors
UY34094A (en) 2011-05-27 2013-01-03 Novartis Ag Piperidine derivatives spirocyclic 3-receptor agonists of ghrelin
US9096684B2 (en) 2011-10-18 2015-08-04 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
EP2819688A4 (en) 2012-02-15 2015-10-28 Aileron Therapeutics Inc Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
US8927500B2 (en) 2012-02-15 2015-01-06 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
PE20142443A1 (en) 2012-05-03 2015-01-28 Novartis Ag L-malate salt derivatives 2,7-diazaspiro [4.5] dec-7-yl and crystalline forms thereof as agonists of the ghrelin receptor
US9604919B2 (en) 2012-11-01 2017-03-28 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
US10471120B2 (en) 2014-09-24 2019-11-12 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
AU2016235424A1 (en) 2015-03-20 2017-10-05 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206235A (en) * 1991-03-20 1993-04-27 Merck & Co., Inc. Benzo-fused lactams that promote the release of growth hormone
US5283241A (en) * 1992-08-28 1994-02-01 Merck & Co., Inc. Benzo-fused lactams promote release of growth hormone
AU684878B2 (en) * 1993-11-24 1998-01-08 Merck & Co., Inc. Compounds and the use thereof to promote the release of growth hormone(s)
US5492916A (en) * 1993-12-23 1996-02-20 Merck & Co., Inc. Di- and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
TW432073B (en) * 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
WO1997034604A1 (en) * 1996-03-21 1997-09-25 Merck & Co., Inc. 4-spiroindoline piperidines promote release of growth hormone
CA2253390A1 (en) * 1996-05-07 1997-11-13 Merck & Co., Inc. Enhancement of sleep with a growth hormone secretagogue
EP1001970B1 (en) * 1997-06-25 2007-03-07 Pfizer Inc. Dipeptide derivatives as growth hormone secretagogues
US6358951B1 (en) * 1998-08-21 2002-03-19 Pfizer Inc. Growth hormone secretagogues

Also Published As

Publication number Publication date
CA2350857A1 (en) 2001-12-19
EP1166778A3 (en) 2003-09-17
AU5198301A (en) 2001-12-20
EP1166778A2 (en) 2002-01-02
US20020013320A1 (en) 2002-01-31
ZA200104923B (en) 2002-12-17
HU0102500A2 (en) 2002-04-29
HU0102500A3 (en) 2003-09-29
JP2002053493A (en) 2002-02-19

Similar Documents

Publication Publication Date Title
DE60108262D1 (en) Alarmchip and method of use thereof
DE60040683D1 (en) Thermal imaging of fat and muscle tissue
DE60024588D1 (en) Substituted porphyrines and their therapeutic uses
DE60132429D1 (en) Pluripotential stem cells generates from fat calves and their uses
DE69928678D1 (en) Use of growth factors and hormones for the improvement of human chondrocytes and cartilage tissue manufacture
DE60036803D1 (en) Arylmethyl-carbonylamino-thiazone derivatives and their use as antitum-means
DE69927969D1 (en) Controlled release of liponic acid
DE60124322D1 (en) Selective modulators of the andro gene receptor and methods of their use
DE60222671D1 (en) Thienopyrimidinedione and its use in the treatment of autoimmune diseases
DE60126923D1 (en) Therapeutic compositions comprising anti-hypotensiva and antiangiogenica
DE60136181D1 (en) 3'-prodrugs of 2'-deoxy-beta-l-nucleosides
DE60123392D1 (en) Improved defense and humidificant
DE60023128D1 (en) Pyrazolecarboxamide for the treatment of fatibility and other diseases
DE60140377D1 (en) Mch antagonists and its use for the treatment of fatibility
DE60113562D1 (en) Men's underwear with adjustable supporting straps
DE60141339D1 (en) Oxide derivatives and its use as latent water
DE60115114D1 (en) Graphite nanofiber and its use
DE69941113D1 (en) Cytokines and mitogenes to prevent "graft-versus-host disease"
DE69942774D1 (en) Use of bioadhaesives and adjuvanties for the mucosal application of antigenes
DE60039291D1 (en) Camptothecinanaloges and their preparation methods
DE60024660D1 (en) Human rnase h and corresponding oligonucleotide compounds
DE60123041D1 (en) Anti-inflammatory compounds and their use
IL140803D0 (en) Compositions and methods of treatment for conditions responsive to testosterone elevation
AU4162902A (en) Reticulated and controlled porosity battery structures
AU9487601A (en) Direct growth of nanotubes, and their use in nanotweezers